Literature DB >> 23295930

Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.

Kitty Wu1, Yvonne C W Yau, Larissa Matukas, Valerie Waters.   

Abstract

Stenotrophomonas maltophilia is a multidrug-resistant organism increasingly isolated from the lungs of cystic fibrosis (CF) patients. One hundred twenty-five S. maltophilia isolates from 85 CF patients underwent planktonic and biofilm susceptibility testing against 9 different antibiotics, alone and in double antibiotic combinations. When S. maltophilia isolates were grown as a biofilm, 4 of the 10 most effective antibiotic combinations included high-dose levofloxacin and 7 of the 10 combinations included colistin at doses achievable by aerosolization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295930      PMCID: PMC3591893          DOI: 10.1128/AAC.02215-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms.

Authors:  H Ceri; M E Olson; C Stremick; R R Read; D Morck; A Buret
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

2.  Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia.

Authors:  K Weiss; C Restieri; E De Carolis; M Laverdière; H Guay
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

3.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

4.  The pharmacokinetics of colistin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; M A O'Riordan; J L Blumer
Journal:  J Clin Pharmacol       Date:  2001-06       Impact factor: 3.126

5.  Stenotrophomonas maltophilia in cystic fibrosis patients.

Authors:  S Ballestero; I Vírseda; H Escobar; L Suárez; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

Review 6.  Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets.

Authors:  Daniel J Hassett; John Cuppoletti; Bruce Trapnell; Sergei V Lymar; John J Rowe; Sang Sun Yoon; George M Hilliard; Kislay Parvatiyar; Moneesha C Kamani; Daniel J Wozniak; Sung Hei Hwang; Timothy R McDermott; Urs A Ochsner
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

Review 7.  The clinical use of colistin in patients with cystic fibrosis.

Authors:  P Beringer
Journal:  Curr Opin Pulm Med       Date:  2001-11       Impact factor: 3.155

Review 8.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

9.  Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime.

Authors:  Giovanni Di Bonaventura; Ilaria Spedicato; Domenico D'Antonio; Iole Robuffo; Raffaele Piccolomini
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.

Authors:  Pablo San Gabriel; Juyan Zhou; Setareh Tabibi; Yunhua Chen; Marco Trauzzi; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  20 in total

1.  In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Anina Ratjen; Yvonne Yau; Jillian Wettlaufer; Larissa Matukas; James E A Zlosnik; David P Speert; John J LiPuma; Elizabeth Tullis; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

2.  Phosphoglycerate mutase affects Stenotrophomonas maltophilia attachment to biotic and abiotic surfaces.

Authors:  Layla Ramos-Hegazy; Shubham Chakravarty; Gregory G Anderson
Journal:  Microbes Infect       Date:  2019-08-17       Impact factor: 2.700

3.  Evaluating Metabolic Pathways and Biofilm Formation in Stenotrophomonas maltophilia.

Authors:  Cierra M Isom; Blake Fort; Gregory G Anderson
Journal:  J Bacteriol       Date:  2021-10-11       Impact factor: 3.476

Review 4.  Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-09

5.  Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.

Authors:  Sean K Tom; Yvonne C W Yau; Trevor Beaudoin; John J LiPuma; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

6.  Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.

Authors:  Sarah Kennedy; Trevor Beaudoin; Yvonne C W Yau; Emma Caraher; James E A Zlosnik; David P Speert; John J LiPuma; Elizabeth Tullis; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

Review 7.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

8.  Molecular Insight into Gene Response of Diorcinol- and Rubrolide-Treated Biofilms of the Emerging Pathogen Stenotrophomonas maltophilia.

Authors:  Mirja Gudzuhn; Ifey Alio; Raphael Moll; Jessica de Vries; Jacob Boehlich; Maik Assmann; Jasmin Janneschütz; Nina Schützenmeister; Axel Himmelbach; Anja Poehlein; Rolf Daniel; Wolfgang R Streit
Journal:  Microbiol Spectr       Date:  2022-04-26

9.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

Review 10.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.